Translational Development Acquisition (TDACW) Payables (2023 - 2026)

Translational Development Acquisition (TDACW) has reported Payables for 4 consecutive years, with $1.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 872.74% year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2026 stood at $1.6 million (up 872.74% YoY), and the FY2025 full-year result was $362311.0, up 2138.01% from the prior year.
• Payables improved to $1.6 million in Q2 2026 per TDACW's latest filing, from $724323.0 in the prior quarter.
• Across five years, Payables topped out at $1.6 million in Q2 2026 and bottomed at $16189.0 in Q4 2024.
• Historically, Payables has averaged $461980.4 across 4 years, with a median of $309917.5 in 2023.
• The sharpest annual moves came in 2024 and 2025: Payables tumbled 95.36% in 2024, then jumped 2138.01% in 2025.
• Over 4 years, Payables stood at $348752.0 in 2023, then sank by 95.36% to $16189.0 in 2024, then surged by 2138.01% to $362311.0 in 2025, then soared by 337.41% to $1.6 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $1.6 million, $724323.0, and $362311.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.